Tofogliflozin

Drug Profile

Tofogliflozin

Alternative Names: Apleway; CSG452; Deberza; R 7201; RG 7201; RO4998452; Tofogliflozin hydrate

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Kowa
  • Class Antihyperglycaemics; Benzhydryl compounds; Benzofurans; Glucosides; Small molecules; Spiro compounds
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 03 Jan 2017 Phase-II clinical trials in Type-2 diabetes mellitus in European Union, USA (PO)
  • 09 Nov 2015 Chugai and Kowa Company agree to co-promote and co-develop tofogliflozin in USA and European Union for Type-2 diabetes mellitus
  • 05 Sep 2015 Launched for Type-2 diabetes mellitus in Japan (PO) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top